Darovasertib
- Generic Name
- Darovasertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23F3N8O
- CAS Number
- 1874276-76-2
- Unique Ingredient Identifier
- E0YF0M8O09
- Background
IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions).
- Associated Conditions
- -
- Associated Therapies
- -
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 82
- Registration Number
- NCT05907954
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Anthony Joshua, FRACP
- Target Recruit Count
- 15
- Registration Number
- NCT05187884
- Locations
- 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath